Hola,
Are you new here?

I have an account

Conecta con

+150K Projects

+300K Companies

+230 Financiaciones

¿Te ayudamos?

Ejemplos de búsqueda

Vídeos Explicativos

MABank

financed

Closed

Creation of a GLP bank of immune-privileged, immortal mesoangioblasts to treat m...

Creation of a GLP bank of immune-privileged, immortal mesoangioblasts to treat monogenic, recessive diseases of muscle and connective tissue Stem cells led to effective cures for diseases of blood and epithelia. However, in the case of diseases affecting muscles, connective tissue or brain, significant challenges persist for expansion of a sufficient number of correcte... see more

28/02/2025

OSR

150K€

Project Budget: 150K€

Project leader

OSPEDALE SAN RAFFAELE SRL No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

PARTICIPATION DEPralty Sin fecha límite de participación.

Ver 2 Participantes

Financing granted El organismo HORIZON EUROPE notifico la concesión del proyecto The day 2025-02-28

ERC-2023-POC: ERC PROOF OF CONCEPT GRANTS Objective:Objectives:The ERC Proof of Concept Grants aim at facilitating exploration of the commerci...

I+D

Cerrada

0% 100% 100%

characteristics of the participant

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Private Information

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

OSR

115.00K€ | Leader

DAY ONE

35.00K€ | participant

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Project duration: 17 months Date Start: 2023-08-31
End date: 2025-02-28

Project leader

OSPEDALE SAN RAFFAELE SRL No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Project Budget 150K€

participation deadline Sin fecha límite de participación.

Project description Stem cells led to effective cures for diseases of blood and epithelia. However, in the case of diseases affecting muscles, connective tissue or brain, significant challenges persist for expansion of a sufficient number of corrected cells, delivery and engraftment. Even when these problems will be solved the prospective per-patient cost of the treatment (up to 2M$) will make such therapies unsustainable for NHS. We developed protocols of cell therapy using mesoangioblasts (Mabs), vessel associated progenitors that, despite promising results in animal models, showed modest efficacy in patients. To address this, we transplanted autologous dystrophic Mabs expressing a small nuclear RNA engineered to skip dystrophin exon 51, that enters and corrects also neighboring nuclei of the multinucleated muscle fiber, thus bringing dystrophic production to therapeutic levels. A Phase I/IIa trial is currently running. Even in case of success, the cost would remain prohibitive. Through the ongoing ERC ADG 884952-UniMab, we are completing the development of immortal, immune-privileged Mabs from dystrophic patients thanks to genome editing of HLA and the expression of tolerogenic proteins. In this PoC project we will produce universal Mabs from healthy donors and will study the feasibility of producing and storing a large amount of universal Mabs through a bank of universal donor Mabs from healthy patients, ready to be corrected for the specific genetic mutation and injected into the patient following the motto one serve many. Available cells, a GMP-grade lentivector, expressing the wt cDNA of the mutated gene and a mouse model for pre-clinical tests would be sufficient to start a trial even for extremely rare diseases that currently lack even the hope of a therapy. This work will enable the business exploitation of the MABANK technology, by creating a company with a GMP biobank that may operate internally and make cells available to clinicians and Biotech companies.

Conecta tu I+D

Entra hoy

Forgot your password?

Financing

Companies

CTIs/Universidades

Projects

researchers

What is innovating.Works? Lose yourself in the best search engine for innovative companies you've ever seen, see how your competition is funded, connect with that partner you didn't know about, discover R&D projects that need you, and much, much more just a click away.

Smart Company-Financial Motor Innovating tiene un perfil tecnológico financiero de 400.000 empresas gracias al cual sabe a qué ayuda puede ir o no cualquier empresa de forma automática. Parece magia pero es tecnología.

Create your project and find partners ¿Tienes un proyecto y buscas un partner? Una Universidad, Centro Tecnológico, Consultoría? Este es tu sitio. Gracias al motor de búsqueda podemos recomendarte los mejores socios y ponerte en contacto con ellos.